Dr. Tarantino was invited to share insights with fellow physicians by responding to a survey specifically tailored for Canadian oncologists. The survey focused on addressing key questions related to HER2-Low Breast Cancer and the DESTINY BREAST Trial, and Dr. Tarantino provides his expert responses here.
Paolo Tarantino is a MD and researcher at the European Institute of Oncology (Milan, Italy) and clinical research fellow at the Dana-Farber Cancer Institute (Boston, MA). His main areas of research are breast cancer, HER2 oncogene and antibody-drug conjugates.
Dr. Tarantino is a leading researcher in the field of breast cancer, with over 50 papers published on the topic. He’s currently pursuing an advanced research fellowship at Dana-Farber Cancer Institute and at Harvard Medical School (Boston, MA).
He is also concomitantly pursuing a PhD in clinical research at the University of Milan.
His research focuses on the study of the HER2 oncoprotein, the emerging HER2-low subgroup of breast tumors and the development of novel antibody-drug conjugates to treat every subtype of breast cancer.
This is a joint educational initiative between the McPeak-Sirois Group and oncoXchange
Supporter acknowledgment: This series is sponsored by AstraZeneca Canada Inc. and is intended for healthcare practitioners only.
This event is sponsored by: :